These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct]. MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856 [No Abstract] [Full Text] [Related]
10. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues). Dharmalingam M; Kumar P J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605 [No Abstract] [Full Text] [Related]
11. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. Fisher M Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621 [TBL] [Abstract][Full Text] [Related]
12. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin. Blonde L; Sandberg MI; Guthrie RD Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262 [No Abstract] [Full Text] [Related]
13. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944 [TBL] [Abstract][Full Text] [Related]
14. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Jones TA; Sautter M; Van Gaal LF; Jones NP Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023 [TBL] [Abstract][Full Text] [Related]
16. [Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance]. Oberpichler-Schwenk H Med Monatsschr Pharm; 1999 Sep; 22(9):288-9. PubMed ID: 10577070 [No Abstract] [Full Text] [Related]
17. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. van Dieren S; Czernichow S; Chalmers J; Kengne AP; de Galan BE; Poulter N; Woodward M; Beulens JW; Grobbee DE; van der Schouw YT; Zoungas S Diabetes Obes Metab; 2012 May; 14(5):464-9. PubMed ID: 22226008 [TBL] [Abstract][Full Text] [Related]
18. Guidance on rosiglitazone for type 2 diabetes mellitus. Matthews DR Lancet; 2001 Feb; 357(9254):481. PubMed ID: 11273100 [No Abstract] [Full Text] [Related]
19. A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study. Halimi S; Aubert JP; Fontbonne A; Guillausseau PJ; Nachit F; Bouée S; Detournay B Diabetes Metab; 2012 Oct; 38(4):343-51. PubMed ID: 22521038 [TBL] [Abstract][Full Text] [Related]
20. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients. Murase Y; Wakasugi T; Yagi K; Mabuchi H Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989 [No Abstract] [Full Text] [Related] [Next] [New Search]